European Surgery

, 39:158 | Cite as

Is immunotherapy a reasonable approach for the treatment of esophageal cancer?

  • J. FriedlEmail author
  • S. Riss
  • A. Stift
Main Topic


BACKGROUND: The advances in surgical techniques and the development of new therapeutic agents have improved the prognosis of esophageal cancer in the past decades. However, the 5 year overall survival still remains poor. The bleak prognosis has led to the search for new therapeutic options such as immunotherapy. METHODS: Review of the literature and presentation of institutional experience in immunotherapy. RESULTS: In the past two decades, adoptive immunotherapy based on tumor infiltrating lymphocytes (TILs) or lymphokine activated killer cells (LAK) has been used in clinical trials. The increasing knowledge about the central role of professional antigen presenting cells (Dendritic cells; DCs) in the regulation of the immune system and the mechanism controlling the function of the involved effector cells have provided new possibilities for cancer treatment. CONCLUSIONS: Immunotherapy in combination with established therapeutical modalities is a possible approach for the treatment of esophageal cancer that may in the future further improve the prognosis.


Esophageal cancer Immunotherapy Dendritic cells Antibodies 

Immuntherapie beim Ösophagus Karzinom


GRUNDLAGEN: Die Fortschritte der chirurgischen Techniken und die Anwendung diverser Chemotherapeutika haben zwar die Prognose des Ösophaguskarzinoms in den letzten Jahrzehnten verbessert, jedoch ist das 5 Jahresüberleben noch immer schlecht. Diese Tatsache hat zur Erforschung von neuen Therapieoptionen wie zum Beispiel Immunotherapie geführt. METHODIK: Literaturübersicht und Darstellung eigener Erfahrungen mit Immuntherapie. ERGEBNISSE: In den letzten zwei Jahrzehnten wurden in klinischen Studien die adoptive Immuntherapie unter Verwendung von Tumor-infiltrierenden Lymphozyten oder Lymphokin aktivierten Killerzellen angewendet: Das zunehmende Verständnis über die zentrale Rolle von professio-nellen antigen-präsentierenden Zellen (dendritische Zellen; DCs) in der Regulation des Immunsystems und die Mechanismen, welche die Funktion der beteiligten Effektorzellen kontrollieren öffnet neue Therapieoptionen bei Tumorpatienten. SCHLUSSFOLGERUNGEN: Die Immuntherapie in Kombination mit etablierten Therapiemodalitäten scheint ein möglicher Therapieansatz in der Behandlung des Ösophaguskarzinoms zu sein, der die Prognose zukünftig noch verbessern sollte.


Ösophaguskarzinom Immuntherapie Dendritische Zellen Antikörper 


  1. Ferlay J, Bray F, Pisani P, GLOBOCAN (2000) Cancer Incidence, Mortality and Prevalence WorldwideGoogle Scholar
  2. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392: 245–252PubMedCrossRefGoogle Scholar
  3. Lotze MAT (1999) Dendritic cells; Biology and Clinical ApplicationGoogle Scholar
  4. Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90: 3245–3287PubMedGoogle Scholar
  5. McCabe ML, Dlamini Z (2005) The molecular mechanisms of oesophageal cancer. Int Immunopharmacol 5: 1113–1130PubMedCrossRefGoogle Scholar
  6. Nakamura T, Hayashi K, Ota M, Ide H, Takasaki K, Mitsuhashi M (2004) Expression of p21(Waf1/Cip1) predicts response and survival of esophageal cancer patients treated by chemoradiotherapy. Dis Esophagus 17: 315–321PubMedCrossRefGoogle Scholar
  7. Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, Hofler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59: 631–634PubMedCrossRefGoogle Scholar
  8. Sato S, Noguchi Y, Wada H, Fujita S, Nakamura S, Tanaka R, Nakada T, Hasegawa K, Nakagawa K, Koizumi F, Ono T, Nouso K, Jungbluth A, Chen YT, Old LJ, Shiratori Y, Nakayama E (2005) Quantitative real-time RT-PCR analysis of NY-ESO-1 and LAGE-1a mRNA expression in normal tissues and tumors, and correlation of the protein expression with the mRNA copy number. Int J Oncol 26: 57–63PubMedGoogle Scholar
  9. Zambon A, Mandruzzato S, Parenti A, Macino B, Dalerba P, Ruol A, Merigliano S, Zaninotto G, Zanovello P (2001) MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 91: 1882–1888PubMedCrossRefGoogle Scholar
  10. Tanaka F, Fujie T, Tahara K, Mori M, Takesako K, Sette A, Celis E, Akiyoshi T (1997) Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57: 4465–4468PubMedGoogle Scholar
  11. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, Old LJ, Knuth A (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97: 12198–12203PubMedCrossRefGoogle Scholar
  12. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H (2005) Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 92: 1253–1260PubMedCrossRefGoogle Scholar
  13. Hanawa M, Suzuki S, Dobashi Y, Yamane T, Kono K, Enomoto N, Ooi A (2006) EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118: 1173–1180PubMedCrossRefGoogle Scholar
  14. Nie Y, Yang G, Song Y, Zhao X, So C, Liao J, Wang LD, Yang CS (2001) DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22: 1615–1623PubMedCrossRefGoogle Scholar
  15. Ramsdell F, Fowlkes BJ (1990) Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 248: 1342–1348PubMedCrossRefGoogle Scholar
  16. Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, Kuniyasu Y, Nomura T, Toda M, Takahashi T (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 182: 18–32PubMedCrossRefGoogle Scholar
  17. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M (2003) Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 987: 15–25PubMedCrossRefGoogle Scholar
  18. Steinman RM, Hawiger D, Nussenzweig MC (2003) Tolerogenic dendritic cells. Annu Rev Immunol 21: 685–711PubMedCrossRefGoogle Scholar
  19. Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393: 474–478PubMedCrossRefGoogle Scholar
  20. Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96: 2233–2238PubMedCrossRefGoogle Scholar
  21. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C (1993) B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366: 76–79PubMedCrossRefGoogle Scholar
  22. Linsley PS, Ledbetter JA (1993) The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11: 191–212PubMedGoogle Scholar
  23. Letterio JJ, Roberts AB (1998) Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137–161PubMedCrossRefGoogle Scholar
  24. Ohm JE, Carbone DP (2001) VEGF as a mediator of tumor-associated immunodeficiency. Immunol Res 23: 263–272PubMedCrossRefGoogle Scholar
  25. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH (1997) Induction of tolerance by IL-10-treated dendritic cells. J Immunol 159: 4772–4780PubMedGoogle Scholar
  26. Takahashi A, Kono K, Ichihara F, Sugai H, Fujii H, Matsumoto Y (2004) Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol Immunother 53: 543–550PubMedCrossRefGoogle Scholar
  27. Jonuleit H, Schmitt E, Steinbrink K, Enk AH (2001) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 22: 394–400PubMedCrossRefGoogle Scholar
  28. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9: 4404–4408PubMedGoogle Scholar
  29. Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, Omata H, Fujii H (2006) CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother 55: 1064–1071PubMedCrossRefGoogle Scholar
  30. Valzasina B, Piconese S, Guiducci C, Colombo MP (2006) Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25− lymphocytes is thymus and proliferation independent. Cancer Res 66: 4488–4495PubMedCrossRefGoogle Scholar
  31. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328–332PubMedCrossRefGoogle Scholar
  32. O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW (2003) Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 52: 387–395PubMedGoogle Scholar
  33. Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Brostjan C, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J (2004) Dendritic cell vaccination in medullary thyroid carcinoma. Clin Cancer Res 10: 2944–2953PubMedCrossRefGoogle Scholar
  34. Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M (2003) Dendritic cell-based vaccination in solid cancer. J Clin Oncol 21: 135–142PubMedCrossRefGoogle Scholar
  35. Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant MF (2000) Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother Radiopharm 15: 477–486PubMedGoogle Scholar
  36. Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann SF, Pfragner R, Gnant M, Friedl J, Stift A (2006) Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma. J Clin Endocrinol Metab 91: 4571–4577PubMedCrossRefGoogle Scholar
  37. Sallusto F, Cella M, Danieli C, Lanzavecchia A (1995) Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 182: 389–400PubMedCrossRefGoogle Scholar
  38. Stingl G, Maurer D (1997) IgE-mediated allergen presentation via Fc epsilon RI on antigen-presenting cells. Int Arch Allergy Immunol 113: 24–29PubMedCrossRefGoogle Scholar
  39. Maurer D, Ebner C, Reininger B, Petzelbauer P, Fiebiger E, Stingl G (1997) Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol 417: 175–178PubMedGoogle Scholar
  40. Brossart P, Bevan MJ (1997) Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90: 1594–1599PubMedGoogle Scholar
  41. Hart DN, Schultze JL, Stewart AK (1999) Presentation of tumor antigens. Semin Hematol 36: 21–25PubMedGoogle Scholar
  42. Basu S, Srivastava PK (1999) Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 189: 797–802PubMedCrossRefGoogle Scholar
  43. Binder RJ, Harris ML, Menoret A, Srivastava PK (2000) Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells. J Immunol 165: 2582–2587PubMedGoogle Scholar
  44. Menoret A, Chandawarkar RY, Srivastava PK (2000) Natural autoantibodies against heat-shock proteins hsp70 and gp96: implications for immunotherapy using heat-shock proteins. Immunology 101: 364–370PubMedCrossRefGoogle Scholar
  45. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 20: 561–567PubMedCrossRefGoogle Scholar
  46. Koch F, Heufler C, Kampgen E, Schneeweiss D, Bock G, Schuler G (1990) Tumor necrosis factor alpha maintains the viability of murine epidermal Langerhans cells in culture, but in contrast to granulocyte/macrophage colony-stimulating factor, without inducing their functional maturation. J Exp Med 171: 159–171PubMedCrossRefGoogle Scholar
  47. Wurtzen PA, Nissen MH, Claesson MH (2001) Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production. Scand J Immunol 53: 579–587PubMedCrossRefGoogle Scholar
  48. Mosmann TR, Sad S (1996) The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 17: 138–146PubMedCrossRefGoogle Scholar
  49. Sato K, Yamashita N, Matsuyama T (2002) Human peripheral blood monocyte-derived interleukin-10-induced semi-mature dendritic cells induce anergic CD4(+) and CD8(+) T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fragments. Cell Immunol 215: 186–194PubMedCrossRefGoogle Scholar
  50. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, Stewart C, Sarmiento U, Faherty DA, Gately MK (1996) IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 4: 471–481PubMedCrossRefGoogle Scholar
  51. Cheever MA, Thompson DB, Klarnet JP, Greenberg PD (1986) Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med 163: 1100–1112PubMedCrossRefGoogle Scholar
  52. Trinchieri G (1995) Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 13: 251–276PubMedCrossRefGoogle Scholar
  53. Croft M, Carter L, Swain SL, Dutton RW (1994) Generation of polarized antigen-specific CD8 effector populations: reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180: 1715–1728PubMedCrossRefGoogle Scholar
  54. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, et al (1994) Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 153: 1697–1706PubMedGoogle Scholar
  55. Smyth MJ, Taniguchi M, Street SE (2000) The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol 165: 2665–2670PubMedGoogle Scholar
  56. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5: 405–411PubMedCrossRefGoogle Scholar
  57. Merogi AJ, Marrogi AJ, Ramesh R, Robinson WR, Fermin CD, Freeman SM (1997) Tumor-host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28: 321–331PubMedCrossRefGoogle Scholar
  58. Yasunaga M, Tabira Y, Nakano K, Iida S, Ichimaru N, Nagamoto N, Sakaguchi T (2000) Accelerated growth signals and low tumor-infiltrating lymphocyte levels predict poor outcome in T4 esophageal squamous cell carcinoma. Ann Thorac Surg 70: 1634–1640PubMedCrossRefGoogle Scholar
  59. Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF (2005) Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J Immunother 28: 258–267PubMedCrossRefGoogle Scholar
  60. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99: 16168–16173PubMedCrossRefGoogle Scholar
  61. Zhou J, Dudley ME, Rosenberg SA, Robbins PF (2005) Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother 28: 53–62PubMedCrossRefGoogle Scholar
  62. Teague RM, Sather BD, Sacks JA, Huang MZ, Dossett ML, Morimoto J, Tan X, Sutton SE, Cooke MP, Ohlen C, Greenberg PD (2006) Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 12: 335–341PubMedCrossRefGoogle Scholar
  63. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162: 2227–2234PubMedGoogle Scholar
  64. Knabel M, Franz TJ, Schiemann M, Wulf A, Villmow B, Schmidt B, Bernhard H, Wagner H, Busch DH (2002) Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med 8: 631–637PubMedCrossRefGoogle Scholar
  65. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA (2005) Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 12: 1005–1016PubMedCrossRefGoogle Scholar
  66. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194: 823–832PubMedCrossRefGoogle Scholar
  67. van Elsas A, Hurwitz AA, Allison JP (1999) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190: 355–366PubMedCrossRefGoogle Scholar
  68. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA (2003) Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 100: 8372–8377PubMedCrossRefGoogle Scholar
  69. Gibault L, Metges JP, Conan-Charlet V, Lozac'h P, Robaszkiewicz M, Bessaguet C, Lagarde N, Volant A (2005) Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer 93: 107–115PubMedCrossRefGoogle Scholar
  70. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G (2006) Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 24: 1612–1619PubMedCrossRefGoogle Scholar
  71. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77–85PubMedCrossRefGoogle Scholar
  72. Sutter AP, Hopfner M, Huether A, Maaser K, Scherubl H (2006) Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. Int J Cancer 118: 1814–1822PubMedCrossRefGoogle Scholar
  73. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354: 567–578PubMedCrossRefGoogle Scholar
  74. Bourhis J, Rivera F, Mesia R, Awada A, Geoffrois L, Borel C, Humblet Y, Lopez-Pousa A, Hitt R, Vega Villegas ME, Duck L, Rosine D, Amellal N, Schueler A, Harstrick A (2006) Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24: 2866–2872PubMedCrossRefGoogle Scholar
  75. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175–184PubMedCrossRefGoogle Scholar
  76. Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R, Wanebo H, Hughes M, Maia C, Tsai JY, Pasquariello T, Pepperell JR, Cioffi W, Kennedy T, Reeder L, Ng T, Adrian A, Goldstein L, Chak B, Choy H (2004) Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 22: 670–677PubMedCrossRefGoogle Scholar
  77. Mimura K, Kono K, Hanawa M, Kanzaki M, Nakao A, Ooi A, Fujii H (2005) Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res 11: 4898–4904PubMedCrossRefGoogle Scholar
  78. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T (2001) Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 92: 663–669PubMedCrossRefGoogle Scholar
  79. Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G, Imamura M (2000) TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 17: 453–460PubMedGoogle Scholar
  80. Kimura S, Kitadai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Toge T, Chayama K (2004) Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 1904–1912PubMedCrossRefGoogle Scholar
  81. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342PubMedCrossRefGoogle Scholar
  82. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24: 1898–1903PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Division of General Surgery, Department of SurgeryMedical University of ViennaViennaAustria

Personalised recommendations